It turns out that AbbVie is only interested in buying Gilgamesh's lead drug programme, a psychedelic candidate for major ...

Nucleus RadioPharma, the radiopharmaceutical-focused contract developing and manufacturing organisation founded by Eclipse ...

A new study published in the Nature journal of Mental Health Research shows powerful real-world evidence for the efficacy of ...

Despite being a rare disease impacting less than a million people worldwide, gMG treatment is an increasingly crowded market, ...

This month’s executive moves in the agency, consultancy, and investor sectors reflect a growing emphasis on strategic leadership, commercial expansion, and specialised expertise in life sciences. From ...

After UK Health Secretary Wes Streeting sent a letter to the pharma industry, warning that he would withdraw from ...

Twin Health has raised another $53 million to fund its 'digital twin' platform, which provides a model of a patient's unique ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...

Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to a price of $499 for those paying for the drugs out of pocket. The ...